4//SEC Filing
Lim Jonathan E 4
Accession 0001415889-25-002957
CIK 0001842295other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:37 PM ET
Size
20.1 KB
Accession
0001415889-25-002957
Insider Transaction Report
Form 4
Lim Jonathan E
Director
Transactions
- Conversion
Common Stock
2025-02-03+270,232→ 307,956 total(indirect: By LLC) - Conversion
Series A Preferred Stock
2025-02-03−363,703→ 0 total(indirect: By LLC)→ Common Stock (37,724 underlying) - Conversion
Common Stock
2025-02-03+37,724→ 37,724 total(indirect: By LLC) - Conversion
Series B Preferred Stock
2025-02-03−2,231,381→ 0 total(indirect: By LLC)→ Common Stock (270,232 underlying) - Award
Stock Option (Right to Buy)
2024-12-09+5,704→ 5,704 totalExercise: $10.42Exp: 2033-03-08→ Common Stock (5,704 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-12-09−5,704→ 0 totalExercise: $17.74Exp: 2033-03-08→ Common Stock (5,704 underlying) - Award
Stock Option (Right to Buy)
2024-12-09+9,086→ 9,086 totalExercise: $10.42Exp: 2034-12-08→ Common Stock (9,086 underlying)
Holdings
- 20,744
Common Stock
Footnotes (7)
- [F1]Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.
- [F2]These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
- [F3]Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.
- [F4]This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.
- [F5]The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
- [F6]This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price.
- [F7]The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Documents
Issuer
Maze Therapeutics, Inc.
CIK 0001842295
Entity typeother
Related Parties
1- filerCIK 0001283290
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 4:37 PM ET
- Size
- 20.1 KB